Ernexa Therapeutics (ERNA) Stock: Buy, Sell, or Hold?
ERNA - Ernexa Therapeutics Inc. Common Stock
$4.17
0.15 (3.61%)
â˛
5d:
-8.06%
30d:
-5.77%
90d:
-36.46%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ERNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ERNA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ERNA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ERNA is currently trading at $4.17, which is considered slightly low relative to its 30-day fair value range of $4.16 to $4.70.
Technical Outlook: Technically, ERNA is showing sideways momentum. Immediate support is located at $3.90, while resistance sits at $4.99. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: ERNA scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+620.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ERNA is showing sideways momentum. Immediate support is located at $3.90, while resistance sits at $4.99. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: ERNA scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+620.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.16 -
$4.70
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 620.3% below Wall St target ($30.00)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.16 -
$4.70
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.90
Resistance Level
$4.99
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.24
Wall Street Target
$30.00
(+620.3%)
Revenue Growth (YoY)
-94.1%
Share & Embed Analysis
Last updated: September 12, 2026 5:43 AM ET
Data refreshes hourly during market hours. Next update: 6:43 AM
Data refreshes hourly during market hours. Next update: 6:43 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
